Author:
Boland I,Vassal G,Morizet J,Terrier-Lacombe M-J,Valteau-Couanet D,Kalifa C,Hartmann O,Gouyette A
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Aaron, R. H., Elion, G. B., Colvin, O. M., Graham, M., Keir, S., Bigner, D. D. & Friedman, H. S. (1994). Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 35: 127–131.
2. Arduino, L. J. & Mellinger, G. T. (1967). Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother Rep 51: 295–304.
3. Berger, D. P., Winterhalter, B. R., Dengler, W. A. & Fiebig, H. H. (1992). Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow. Anticancer Drugs 3: 531–539.
4. Bettan-Renaud, L., Bayle, C., Teyssier, J. R. & Benard, J. (1989). Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835. Int J Cancer 44: 460–466.
5. Bhagwatwar, H. P., Phadungpojna, S., Chow, D. S. L. & Anderson, B. S. (1996). Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 37: 401–408.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献